在中国大型遗传性易栓症家系队列中对抗凝血酶缺乏症的综合研究:发现4种仅损害渐进活性的SERPINC1致病变异
研究对842个中国遗传性易栓症家系同时进行功能检测和基因分析,发现功能检测下抗凝血酶缺乏症患病率为8.6%(72/842),结合基因分析可达10.0%(84/842)。研究鉴定出以渐进活性受损而肝素辅因子活性正常为特征的新II型反应位点亚型,该亚型在含肝素的功能检测中被漏检。
要点
- 842个中国易栓症家系中,功能检测抗凝血酶缺乏症患病率8.6%(72/842),结合基因分析为10.0%(84/842)。
- 静脉血栓栓塞患者中致病性SERPINC1变异检出率为9.3%(78/842)。
- 新发现的II型反应位点亚型表现为渐进活性受损而肝素辅因子活性正常,在含肝素的功能检测中被漏检。
核心结论
- 研究鉴定出一种新的抗凝血酶II型反应位点亚型,以渐进活性受损而肝素辅因子活性正常为特征,在含肝素的功能检测中被漏检。
- 研究结果支持抗凝血酶缺乏症被低估,并强调需要优化当前抗凝血酶缺乏症的诊断流程。
研究设计与样本
- 研究对842个中国遗传性易栓症家系同时进行功能检测和基因分析。
- 采用补充功能检测(渐进检测和凝血酶生成试验)及体外酶学试验检测抗凝血酶缺陷、评估血栓风险并探究所选变异的致病机制。
主要发现
- 共鉴定出72例抗凝血酶活性降低(<80%)的病例,其中66例携带61种不同的SERPINC1变异,6例未发现可识别的变异。
- 在抗凝血酶抗原和活性均正常的15例病例中发现11种变异,包括5例携带3种已知致病变异(p.N224H、p.E227K和p.M313T),7例携带4种与抗凝血酶渐进活性受损相关的变异(p.K289E、p.R293W、p.R294C和p.V295M),以及4种可能良性变异(p.V9I、p.S236L、p.G276A和p.V387I)。
- 功能检测下抗凝血酶缺乏症患病率为8.6%(72/842),结合基因分析后可达10.0%(84/842)。
- 在静脉血栓栓塞患者中,致病性SERPINC1变异检出率为9.3%(78/842)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Congenital antithrombin (AT) deficiency, primarily caused by variants in SERPINC1, is associated with a high risk of venous thromboembolism. Existing diagnostic procedures, mainly based on functional assays, may miss certain pathogenic variants. OBJECTIVES: To comprehensively evaluate AT deficiency prevalence in the Chinese thrombophilia population and identify SERPINC1 variants overlooked by traditional diagnostic procedures. METHODS: We conducted functional assays and genetic analysis simultaneously in 842 Chinese thrombophilia pedigrees. Supplementary functional assays (progressive assay and thrombin generation test) and in vitro enzymatic assays were used to detect AT defects, assess thrombotic risk, and investigate the pathogenic mechanisms of selected variants. RESULTS: We identified 72 cases with decreased AT activity (<80%), of which 66 cases carried 61 different SERPINC1 variants, while 6 lacked identifiable variants. Additionally, 11 variants were found in 15 cases with normal AT antigen and activity, including 3 known pathogenic variants (p.N224H, p.E227K, and p.M313T) in 5 cases, 4 variants (p.K289E, p.R293W, p.R294C, and p.V295M) associated with impaired AT progressive activity in 7 cases, and 4 likely benign variants (p.V9I, p.S236L, p.G276A, and p.V387I). Thus, the prevalence of AT deficiency was 8.6% (72/842) by functional assays, and could reach 10.0% (84/842) when incorporating genetic analysis. Pathogenic SERPINC1 variants were found in 9.3% (78/842) of venous thromboembolism patients. CONCLUSION: We identified a new AT type II reactive-site subtype, characterized by impaired progressive activity but normal heparin cofactor activity, which is overlooked in heparin-containing functional assays. These findings support that AT deficiency is underestimated and highlight the need to optimize current diagnostic algorithm for AT deficiency.
引用
- Chen C, Wu X, Li L, et al. A comprehensive study of antithrombin deficiency in a large cohort of Chinese thrombophilia pedigrees: uncovering 4 SERPINC1 pathogenic variants merely impaired progressive activities. J Thromb Haemost. 2025. PMID: 40339963. doi:10.1016/j.jtha.2025.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。